Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 7/2009

01-07-2009 | Translational Research and Biomarkers

Preoperative u-PAR Gene Expression in Bone Marrow Indicates the Potential Power of Recurrence in Breast Cancer Cases

Authors: Koshi Mimori, MD, PhD, Akemi Kataoka, MD, PhD, Hiroshi Yamaguchi, MD, PhD, Norikazu Masuda, MD, PhD, Yoshimasa Kosaka, MD, PhD, Hideshi Ishii, MD, PhD, Shinji Ohno, MD, PhD, Masaki Mori, MD, PhD, FACS

Published in: Annals of Surgical Oncology | Issue 7/2009

Login to get access

ABSTRACT

Introduction

The clinical significance of isolated tumor cells (ITC) in peripheral blood (PB) and bone marrow (BM) as predictive markers in the recurrence or metastasis of breast cancer has not yet been determined. In the current study, we focused on the urokinase plasminogen activator receptor (u-PAR) gene as a powerful indicator of the potential to relapse after surgery.

Patients and Methods

We examined CK-7 and CK19 as an ITC marker and u-PAR as a candidate indicator for metastasis in PB and BM from 800 cases of breast cancer by quantitative real-time reverse-transcription polymerase chain reaction (RT-PCR). Serum tumor markers, carcinoembryonic antigen (CEA) and cancer antigen 15-3 (CA15-3), were compared with u-PAR or CK status.

Results

CK7 in PB was positive in 262 cases that showed a poorer disease-free survival (DFS) than 478 CK7(–) cases (P < 0.05). The 153 cases of u-PAR(+) in BM showed significantly poorer DFS and overall survival (OS) than did the 579 cases of u-PAR(–) in BM (P < 0001 and P < 0.0001, respectively). In PB, a significant difference was also observed between 330 cases of u-PAR(+) and 437 cases of u-PAR(–) (P < 0.0001). The hazard ratio (HR) for prediction of recurrence was significantly higher in u-PAR (P < 0.0001; HR 0.0519) than the level of three serum tumor markers.

Discussion

u-PAR expresses in cancer cells during the dormant phase. The current findings revealed that the expression levels of u-PAR in PB and BM evaluated preoperatively indicate the potential to relapse or metastasize after surgery.
Literature
1.
Braun S, Cevatli BS, Assemi C, Janni W, Kentenich CR, Schindlbeck C, et al. Comparative analysis of micrometastasis to the bone marrow and lymph nodes of node-negative breast cancer patients receiving no adjuvant therapy. J Clin Oncol. 2001;19:1468–75.PubMed
2.
Braun S, Pantel K, Muller P, et al. Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer. New Eng J Med. 2000;342:525–33.PubMedCrossRef
3.
Mansi JL, Gogas H, Bliss JM, Gazet JC, Berger U, Coombes RC. Outcome of primary-breast-cancer patients with micrometastases: a long-term follow-up study. Lancet. 1999;354:197–202.PubMedCrossRef
4.
Masuda N, Tamaki Y, Sakita I, et al. Clinical significance of micrometastases in axillary lymph nodes assessed by reverse transcription-polymerase chain reaction in breast cancer patients. Clin Cancer Res. 2000;6:4176–85.PubMed
5.
Molino A, Micciolo R, Turazza M, et al. Prognostic significance of estrogen receptors in 405 primary breast cancers: a comparison of immunohistochemical and biochemical methods. Breast Cancer Res Treat. 1997;45:241–9.PubMedCrossRef
6.
Salvadori B, Squicciarini P, Rovini D, et al. Use of monoclonal antibody MBr1 to detect micrometastases in bone marrow specimens of breast cancer patients. Eur J Cancer. 1990;26:865–7.PubMed
7.
Braun S, Vogl FD, Naume B, et al. A pooled analysis of bone marrow micrometastasis in breast cancer. New Eng J Med. 2005;353:793–802.PubMedCrossRef
8.
Masuda TA, Kataoka A, Ohno S, et al. Detection of occult cancer cells in peripheral blood and bone marrow by quantitative RT-PCR assay for cytokeratin-7 in breast cancer patients. Int J Oncol. 2005;26:721–30.PubMed
9.
Heiss MM, Allgayer H, Gruetzner KU, et al. Individual development and uPA-receptor expression of disseminated tumour cells in bone marrow: a reference to early systemic disease in solid cancer. Nat Med. 1995;1:1035–9.PubMedCrossRef
10.
Allan AL, Vantyghem SA, Tuck AB, Chambers AF. Tumor dormancy and cancer stem cells: implications for the biology and treatment of breast cancer metastasis. Breast Dis. 2006;26:87–98.PubMed
11.
Brackstone M, Townson JL, Chambers AF. Tumour dormancy in breast cancer: an update. Breast Cancer Res. 2007;9:208.PubMedCrossRef
12.
Demicheli R, Retsky MW, Hrushesky WJ, Baum M. Tumor dormancy and surgery-driven interruption of dormancy in breast cancer: learning from failures. Nat Clin Pract Oncol. 2007;4:699–710.PubMedCrossRef
13.
Laufs S, Schumacher J, Allgayer H. Urokinase-receptor (u-PAR): an essential player in multiple games of cancer: a review on its role in tumor progression, invasion, metastasis, proliferation/dormancy, clinical outcome and minimal residual disease. Cell Cycle. Georgetown, Tex 2006;5:1760–71.
14.
Iinuma H, Okinaga K, Egami H, et al. Usefulness and clinical significance of quantitative real-time RT-PCR to detect isolated tumor cells in the peripheral blood and tumor drainage blood of patients with colorectal cancer. Int J Oncol. 2006;28:297–306.PubMed
15.
Holmgren L, O’Reilly M, Folkman J. Dormancy of micrometastases: Balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat Med. 1995;1:149–53.PubMedCrossRef
16.
17.
18.
Uhr J, Scheuermann R, Street N, Vitetta E. Cancer dormancy: opportunities for new therapeutic approaches. Nat Med. 1997;3:505–9.PubMedCrossRef
19.
Riethdorf S, Wikman H, Pantel K. Review: biological relevance of disseminated tumor cells in cancer patients. Int J Oncol. 2008;123:1991–2006.
20.
Wikman H, Vessella R, Pantel K. Cancer micrometastasis and tumour dormancy. Apmis. 2008;116:754–70.PubMedCrossRef
21.
Allgayer H, Aguirre-Ghiso JA. The urokinase receptor (u-PAR)–a link between tumor cell dormancy and minimal residual disease in bone marrow? Apmis. 2008;116:602–14.PubMedCrossRef
22.
Mimori K, Fukagawa T, Kosaka Y, et al. Hematogenous metastasis in gastric cancer requires isolated tumor cells and expression of vascular endothelial growth factor receptor-1. Clin Cancer Res. 2008;14:2609–16.PubMedCrossRef
23.
Peters BA, Diaz LA, Polyak K, et al. Contribution of bone marrow-derived endothelial cells to human tumor vasculature. Nat Med. 2005;11:261–2.PubMedCrossRef
24.
Hildenbrand R, Glienke W, Magdolen V, Graeff H, Stutte HJ, Schmitt M. Urokinase receptor localization in breast cancer and benign lesions assessed by in situ hybridization and immunohistochemistry. Histochem Cell Biol. 1998;110:27–32.PubMedCrossRef
25.
Schlimok G, Funke I, Pantel K, et al. Micrometastatic tumour cells in bone marrow of patients with gastric cancer: methodological aspects of detection and prognostic significance. Eur J Cancer. 1991;27:1461–5.PubMedCrossRef
26.
Dubuisson L, Monvoisin A, Nielsen BS, Le Bail B, Bioulac-Sage P, Rosenbaum J. Expression and cellular localization of the urokinase-type plasminogen activator and its receptor in human hepatocellular carcinoma. J Pathol. 2000;190:190–5.PubMedCrossRef
27.
Pyke C, Graem N, Ralfkiaer E, et al. Receptor for urokinase is present in tumor-associated macrophages in ductal breast carcinoma. Cancer Res. 1993;53:1911–5.PubMed
Metadata
Title
Preoperative u-PAR Gene Expression in Bone Marrow Indicates the Potential Power of Recurrence in Breast Cancer Cases
Authors
Koshi Mimori, MD, PhD
Akemi Kataoka, MD, PhD
Hiroshi Yamaguchi, MD, PhD
Norikazu Masuda, MD, PhD
Yoshimasa Kosaka, MD, PhD
Hideshi Ishii, MD, PhD
Shinji Ohno, MD, PhD
Masaki Mori, MD, PhD, FACS
Publication date
01-07-2009
Publisher
Springer-Verlag
Published in
Annals of Surgical Oncology / Issue 7/2009
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-009-0465-x

Other articles of this Issue 7/2009

Annals of Surgical Oncology 7/2009 Go to the issue

Consensus Report: Resectable and Borderline Resectable Pancreas Cancer

Surgical Treatment of Resectable and Borderline Resectable Pancreatic Cancer: Expert Consensus Statement by Evans et al.

Translational Research and Biomarkers

Radioimmunotherapy Improves Survival of Rats with Microscopic Liver Metastases of Colorectal Origin

Hepatobiliary and Pancreatic Tumors

Perioperative Factors Affecting Long-Term Outcomes of 473 Consecutive Patients Undergoing Hepatectomy for Hepatocellular Carcinoma

Hepatobiliary and Pancreatic Tumors

Survival Outcomes of Patients with Colorectal Liver Metastases Following Hepatic Resection or Ablation in the Era of Effective Chemotherapy

Breast Oncology

Video-Assisted Skin-Sparing Breast-Conserving Surgery for Breast Cancer and Immediate Reconstruction with Autologous Tissue: Clinical Outcomes

Gastrointestinal Oncology

Adjustment of N Stages of Gastric Cancer by the Ratio Between the Metastatic and Examined Lymph Nodes